Praxis Precision Medicines, Inc.
News
Ballentine Partners LLC Buys New Shares in Praxis Precision Medicines, Inc. (NASDAQ:PRAX)
Zolmax Ballentine Partners LLC acquired a new position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with...\n more…
HC Wainwright Reaffirms Buy Rating for Praxis Precision Medicines (NASDAQ:PRAX)
Ticker Report HC Wainwright reissued their buy rating on shares of Praxis Precision Medicines (NASDAQ:PRAX - Free Report) in a research note released on Tuesday morning, Benzinga reports. HC Wainwright currently...\n more…
Reviewing Praxis Precision Medicines (NASDAQ:PRAX) and Revance Therapeutics (NASDAQ:RVNC)
Ticker Report Revance Therapeutics (NASDAQ:RVNC - Get Free Report) and Praxis Precision Medicines (NASDAQ:PRAX - Get Free Report) are both small-cap medical companies, but which is the better investment? We will...\n more…
Equities Analysts Offer Predictions for Praxis Precision Medicines, Inc.'s FY2027 Earnings (NASDAQ:PRAX)
Ticker Report Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) - Stock analysts at Wedbush lifted their FY2027 EPS estimates for shares of Praxis Precision Medicines in a report issued on Tuesday...\n more…
Praxis Precision Medicines to Participate in Upcoming Investor Conferences
Globe Newswire BOSTON, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...\n more…